Name | Number of supported studies | Average coverage | |
---|---|---|---|
adipocyte | 8 studies | 57% ± 12% | |
kidney loop of Henle epithelial cell | 7 studies | 43% ± 14% | |
renal alpha-intercalated cell | 7 studies | 80% ± 13% | |
kidney distal convoluted tubule epithelial cell | 5 studies | 55% ± 11% | |
renal principal cell | 5 studies | 35% ± 12% | |
ionocyte | 4 studies | 34% ± 8% | |
myofibroblast cell | 3 studies | 27% ± 10% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
kidney | 4 studies | 34% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 4819.07 | 457 / 459 | 78% | 15.19 | 877 / 1118 |
kidney | 100% | 7707.03 | 89 / 89 | 60% | 26.86 | 541 / 901 |
stomach | 100% | 3221.84 | 359 / 359 | 34% | 1.88 | 97 / 286 |
adrenal gland | 60% | 569.16 | 155 / 258 | 73% | 15.01 | 169 / 230 |
uterus | 95% | 13062.06 | 162 / 170 | 14% | 2.09 | 66 / 459 |
bladder | 86% | 1271.33 | 18 / 21 | 17% | 0.94 | 87 / 504 |
adipose | 100% | 6093.11 | 1201 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 98% | 3625.60 | 1311 / 1335 | 0% | 0 | 0 / 0 |
intestine | 74% | 1654.17 | 718 / 966 | 20% | 0.91 | 108 / 527 |
pancreas | 49% | 353.23 | 162 / 328 | 43% | 2.19 | 77 / 178 |
esophagus | 59% | 607.66 | 855 / 1445 | 29% | 1.27 | 53 / 183 |
skin | 72% | 1733.99 | 1306 / 1809 | 9% | 0.44 | 41 / 472 |
prostate | 47% | 369.84 | 114 / 245 | 21% | 0.73 | 103 / 502 |
ovary | 19% | 200.94 | 34 / 180 | 37% | 1.99 | 159 / 430 |
lung | 9% | 57.57 | 51 / 578 | 13% | 0.80 | 152 / 1155 |
brain | 13% | 148.03 | 349 / 2642 | 5% | 0.21 | 36 / 705 |
thymus | 9% | 65.06 | 61 / 653 | 8% | 0.39 | 47 / 605 |
tonsil | 0% | 0 | 0 / 0 | 11% | 0.36 | 5 / 45 |
heart | 4% | 24.99 | 31 / 861 | 0% | 0 | 0 / 0 |
liver | 0% | 0 | 0 / 226 | 2% | 0.19 | 10 / 406 |
spleen | 0% | 2.67 | 1 / 241 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.89 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0060455 | Biological process | negative regulation of gastric acid secretion |
GO_0014827 | Biological process | intestine smooth muscle contraction |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
GO_0006954 | Biological process | inflammatory response |
GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
GO_0031622 | Biological process | positive regulation of fever generation |
GO_0008219 | Biological process | cell death |
GO_0007189 | Biological process | adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0005635 | Cellular component | nuclear envelope |
GO_0016020 | Cellular component | membrane |
GO_0004957 | Molecular function | prostaglandin E receptor activity |
Gene name | PTGER3 |
Protein name | Prostaglandin E2 receptor EP3 subtype (Prostanoid EP3 receptor) Prostaglandin E2 receptor EP3 subtype (PGE receptor EP3 subtype) (PGE2 receptor EP3 subtype) (PGE2-R) (Prostanoid EP3 receptor) |
Synonyms | EP3-I hCG_1811960 EP3f |
Description | FUNCTION: Receptor for prostaglandin E2 (PGE2) . The activity of this receptor can couple to both the inhibition of adenylate cyclase mediated by G(i) proteins, and to an elevation of intracellular calcium . Required for normal development of fever in response to pyrinogens, including IL1B, prostaglandin E2 and bacterial lipopolysaccharide (LPS). Required for normal potentiation of platelet aggregation by prostaglandin E2, and thus plays a role in the regulation of blood coagulation. Required for increased HCO3(-) secretion in the duodenum in response to mucosal acidification, and thereby contributes to the protection of the mucosa against acid-induced ulceration. Not required for normal kidney function, normal urine volume and osmolality (By similarity). . |
Accessions | ENST00000370931.7 [P43115-1] ENST00000497146.5 ENST00000628037.2 [P43115-3] P43115 B2KKV4 ENST00000460330.5 [P43115-4] ENST00000356595.8 [P43115-5] Q147U0 A0A0B4J204 O00325 Q5CZ60 ENST00000479353.5 [P43115-7] ENST00000306666.10 [P43115-1] ENST00000370924.5 [P43115-2] Q6TTN3 ENST00000361210.6 Q5CZ57 |